Roswell Park Cancer Institute (RPCI) has enhanced Institute science and education activities over the current period of NCI funding. Critical to this progress has been the availability of the CCSG Developmental Funds which serve to nucleate investment of philanthropic and Institute resources for expansion of science and education. The success of these investments is greatly enhanced by effective RPCI Planning and Evaluation processes that identify and evaluate areas of strategic opportunity and need. These processes engage advisory committees (e.g. CCSG External Advisory Board, program-specific External Advisory Boards, Executive Council, CCSG Steering Committee, Shared Resource Directors Committee, Shared Resource Advisory Committees and Institute Strategic Leadership Retreats). High priority needs are identified, and met through the use of Institute funds and philanthropic resources, with a small but very important component (3%) constituted by CCSG Developmental Funds. Developmental Funds are used to recruit outstanding basic, clinical and population scientists, to enhance shared resource infrastructure and to promote programmatic research in strategic high priority areas. During the award period, these funds were used to recruit 17 new CCSG members, 13 of whom have obtained extramural peer-reviewed project or career-development funding with a return on investment (grant funding) of 24:1. Nine (9) shared resources received developmental funding, and this resulted in more use by investigators, enhanced recruitment efforts and additional peer-reviewed funding opportunities. Sixteen (16) research projects were awarded that to date have generated 6 grants or funded supplements (with a well-scored P50 awaiting funding), 8 publications, 9 abstracts, and 5 clinical trials with a return on investment (grant funding) of 11:1. Institute and CCSG Developmental Funds are complemented by philanthropic funding through the Roswell Park Alliance Foundation (RPAF) to reach key Institute strategic goals. In the next award period, RPCI proposes to utilize CCSG Developmental Funds for continued support of faculty recruitment, shared resources and developmental research. These will be strategically selected in accordance with the RPCI strategic plan and ongoing review by evaluation processes. Dr. Donald Trump, Institute Director, has responsibility for final assignment of CCSG and Institute funds.

Public Health Relevance

To drive growth and innovation, Roswell Park Cancer Institute strategically uses developmental funding to support strategic faculty recruitment, novel pilot projects, and shared resource development. These areas are closely tied to going strategic planning and evaluation efforts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-37
Application #
8738380
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-06-16
Project End
2019-04-30
Budget Start
2014-06-26
Budget End
2015-04-30
Support Year
37
Fiscal Year
2014
Total Cost
$858,627
Indirect Cost
$339,621
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Terakawa, Tomoaki; Katsuta, Eriko; Yan, Li et al. (2018) High expression of SLCO2B1 is associated with prostate cancer recurrence after radical prostatectomy. Oncotarget 9:14207-14218
Zhu, Qianqian; Yan, Li; Liu, Qian et al. (2018) Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation. Blood 131:2490-2499
Visioni, Anthony; Kim, Minhyung; Wilfong, Chandler et al. (2018) Intra-arterial Versus Intravenous Adoptive Cell Therapy in a Mouse Tumor Model. J Immunother 41:313-318
Li, Yanchun; Opyrchal, Mateusz; Yao, Song et al. (2018) The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene. Breast Cancer Res Treat 170:293-302
Mastri, Michalis; Lee, Christina R; Tracz, Amanda et al. (2018) Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors. Mol Cancer Ther 17:1602-1612
Dong, Jing; Levine, David M; Buas, Matthew F et al. (2018) Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. Clin Gastroenterol Hepatol 16:1598-1606.e4
Sass, Stephanie N; Ramsey, Kimberley D; Egan, Shawn M et al. (2018) Tumor-associated myeloid cells promote tumorigenesis of non-tumorigenic human and murine prostatic epithelial cell lines. Cancer Immunol Immunother 67:873-883
Neubauer, Bjoern; Schrankl, Julia; Steppan, Dominik et al. (2018) Angiotensin II Short-Loop Feedback: Is There a Role of Ang II for the Regulation of the Renin System In Vivo? Hypertension 71:1075-1082
Goodrich, Maxwell M; Talhouk, Ramzi; Zhang, Xiaojing et al. (2018) An approach for controlling the timing and order of engineered mutations in mice. Genesis 56:e23243

Showing the most recent 10 out of 1555 publications